Therefore, {HEAD ~ better AR inhibitors} with more potent antagonistic activities and minimal agonistic activities are needed to delay disease progression and to treat {TAIL ~ the fatal hormone refractory prostate cancer} 
are needed to treat
Therefore , { HEAD ~ better AR inhibitors } with more potent antagonistic activities and minimal agonistic activities are needed to delay disease progression and to treat { TAIL ~ the fatal hormone refractory prostate cancer }
OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH REL REL OTH OTH OTH OTH OTH REL REL TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL